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Background: Hypertension is a major health problem worldwide. It can lead to cardiovascular disease and also
leads to functional disturbances including hematological parameters. The abnormalities of haematological parameters
may enhance an end-organ damage. Therefore, the aim of this study was to assess some hematological parameters of
hypertensive individuals in comparison with normotensive individuals at University of Gondar hospital, northwest Ethiopia.
Methods: A cross sectional comparative study was conducted from October to November 2015 on a total of
126 hypertensive and 126 normotensive individuals at University of Gondar Hospital. All participants after taking informed
consent were interviewed for detailed history and 3 ml of blood was collected for hematological test analysis. Independent
t-test and the Mann Whitney u-test were used to find out significant difference and Pearson’s and Spearman’s
correlation were used for correlation test. P values less than 0.05 was considered the level of significance.
Result: From a total of 252 study subjects, about 67.5% were females. The mean age of study subjects was 50.3 ± 11 years
for hypertensive individuals and 49.8 ± 11.6 years for normotensive individuals with range of 18–65 years. In the
present study, the median (IQR) value of WBC, RBC, Hgb, HCT, MCV and the mean value of MCHC, RDW, MPV and
PDW were significantly higher in hypertensive group compared to apparently healthy normotensive groups. Additionally,
WBC, RBC, Hgb, HCT and PLT showed statistically significant positive correlations with blood pressure indices. Platelet
count and MCH did not show statistically significant difference between the two groups.
Conclusion: Hypertension has impact on hematological parameters. In this study, the mean and median values of
haematological parameters in hypertensive individuals were significantly different compared to apparently healthy
normotensive individuals. Hence, hematological parameters can be used to monitor the prognosis of the disease and
manage hypertensive related complications, and it is important to assess hematological parameters for hypertensive
individuals which may help to prevent complications associated hematological disorders.
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Hypertension (HTN) is also called high blood pressure. It is
a condition in which systemic arterial pressure is elevated
above the threshold value [1]. It is expressed by systolic
(maximum) and diastolic (minimum) arterial pressures.
Systolic pressure is occurring during contraction of the left
ventricle of the heart while diastolic pressure is occurring
before the next contraction. Normally at rest the systolic
pressure is within 100–140 mm mercury (mmHg) and dia-
stolic pressure is within 60–90 mmHg [2, 3]. Based on the
seventh Joint National Committee (7 JNC) report in
2008, normal HTN was defined as systolic blood
pressure (SBP) < 120 mmHg and diastolic blood pres-
sure (DBP) < 80 mmHg, pre-HTN with SBP of
120-139 mmHg or DBP 80–89 mmHg, stage I HTN
with SBP of 140–159 mmHg or DBP 90–99 mmHg
and stage II HTN with SBP ≥ 160 mmHg or DBP ≥
100 mmHg [1, 4].
HTN can be categorized in to two; primary and second-
ary hypertensions. Primary HTN, which consists of about
95% cases, can occur without any obvious underlying
causes while secondary HTN is developed due to second-
ary to diseases such as kidney disease, endocrine disorders
and narrowing of the aorta or kidney arteries [5, 6].
HTN is a major health problem worldwide that affects
20–30% of the adult population [7]. It is rapidly increased
from 3% in rural areas to 30% in urban areas of
Sub-Saharan Africa. In 2008, its overall prevalence rate in
Sub Saharan Africa was 16.2% ranging from 10.6%
(Ethiopia) to 26.9% (Ghana) [8–10].
HTN may lead to severe end-organ damage, coronary
heart disease and stroke which constitute the leading
cause of mortality [11, 12]. It is strongly associated with
functional and structural abnormalities to organs that
involve in hematopoiesis [5, 6, 13] and blood viscosity is
increased in most hypertensive patient’s [14]. Although,
the details of this association is unclear, development of
HTN is accompanied by reduction in deformability, and
an increase in size, number and aggregability of red
blood cells. These abnormalities of the red cells may
worsen the microcirculation and enhance an end-organ
damage [11, 15].
On the other hand, HTN has an impact on
hematological parameter such as hematocrit (HCT),
hemoglobin (Hgb), red blood cell (RBC) count, white
blood cell (WBC) count and platelet (PLT) count. Im-
paired hematological parameters may strongly indicate
hypertensive end-organ damage, specifically kidney fail-
ure [7, 16, 17]. Specifically increased Hgb level may
cause left ventricular hypertrophy while low Hgb levels
causes anemia and heart failure [18].
Generally, there are contradictory results regarding
hematological parameters of hypertensive patients in dif-
ferent countries. Moreover, there is lack of informationregarding to hematological parameters in hypertensive
patients in Ethiopia. Therefore, this study was aimed at
assessing hematological parameters in hypertensive
patients in comparison with apparently healthy individ-
uals and correlating hematological parameters with
blood pressure indices (systolic blood pressure, diastolic
blood pressure and mean arterial pressure) at university
of Gondar hospital, Northwest Ethiopia.
Methods
Study setting, design and population
A comparative cross-sectional study was conducted from
October to November 2015 at university of Gondar
hospital chronic illness clinic. The hospital is located in
Gondar town which is 740 km from the capital of
Ethiopia, Addis Ababa, in the Northwest of Ethiopia.
Gondar University Hospital is the only referral hospital
in North West Ethiopia serving a population of about 5
million. This hospital gives different types of service for
the population including treatment of chronic diseases.
A total of 252 (126 hypertensive confirmed and 126 ap-
parently healthy) study subjects were included conveni-
ently in this study. The study subjects with hypertensive
and healthy controls were age and sex matched. Study
subjects with history of infectious diseases, alcohol con-
sumers, smokers, taking antibiotic, treatment for
anemia, patients with systemic diseases and with second-
ary hypertension were excluded from this study with
face to face interview and review of medical records
(Additional file 1).
Data collection
Socio-demographic and clinical data collection
After taking a written informed consent data were col-
lected by using structured questionnaire and by review-
ing study subjects’ medical record (Additional file 1).
The questionnaire was validated with pre-test.The data
regarding anthropometric variables such as height (to the
nearest centimeter without shoes) and weight (to the
nearest 0.1 kg) were collected and body mass index (BMI)
was calculated as weight in kilograms divided by height in
meter squared. Blood pressure (BP) was measured by
qualified personnel using an analog sphygmomanometer
and stethoscope. All study subjects were recruited during
their respective appointment schedule for follow up and
newly diagnosed individuals. After interview and detailed
review of the medical record, the study subjects were sent
to laboratory where blood was collected for determination
of complete blood cell count.
Laboratory sample collection and analysis
Laboratory analysis was done at University of Gondar
hospital Laboratory. Three milliliters of venous blood
were collected by experienced laboratory technologist
Table 1 Demographic and anthropometric characteristics of study















Sex Male 41 (32.5%) 41 (32.5%)
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count (CBC) was analyzed by using Sysmex KX-21 auto-
mated hematology analyzer. White blood cells (WBC),
red blood cell parameters (RBC, Hgb, HCT, MCV,
MCH, MCHC and RDW) and platelet parameters (PLT,
MPV and PDW) were analyzed and collected for each
study participants by using laboratory result registration
form (Additional file 2).Female 85 (67.5%) 85 (67.5%)
Residence Urban 84 (66.7%) 116 (92.1%)



















The anthropometric and blood pressure measurements
were taken twice and the average value was used. Protocol
for sample collection, processing, and transportation was
strictly followed to have safe procedure and reliable speci-
men. Quality controls and standard operating procedure
were strictly followed for hematological parameter analysis.
The results were properly documented, transcribed and
reviewed.Statistical analysis
Data were cleaned, edited and checked for completeness
and entered in to SPSS version 20 statistical software for
analysis. The normality of data distribution was checked
by statistical tools of Kolmogorov-Smirnov (K-S). The re-
sults were expressed as mean ± standard deviation and
median with interquartile range. Comparison of parame-
ters between hypertensive subjects and apparently healthy
normotensive controls was done with independent t-test
for normally distributed data and Mann-Whitney U test
for non-normally distributed data. The correlation of
hematological parameters with blood pressure indices
(systolic blood pressure, diastolic blood pressure and
mean arterial pressure) was assessed by Pearson’s and
Spearman’s correlation. In any condition, P value < 0.05
was considered as statistically significant.Results
Characteristics of study subjects
A total of 252 study subjects grouped into two groups
(126 Hypertensive and 126 healthy controls) were in-
volved in this study. From them 67.5% (85 hypertensive
and 85 healthy) were female study subjects which makes
1:2 ratio of male to female. The mean age of study sub-
jects was 50.3 ± 11 years for hypertensive individuals and
49.8 ± 11.6 years for apparently healthy individuals with
range of 18–65 years. About 200 (79.4%) of the total
study subjects and 84 (66.7%) of the cases group were
urban dwellers. The mean and standard deviation value
of the BMI, MAP, SBP and DBP were 24.0 ± 2.3, 109.4 ±
5.4 mmHg, 143.2 ± 8.0 mmHg, and 92.4 ± 4.6 mmHg, re-
spectively. The average duration of illness was 3.47 ±
2.8 years (Table 1).Comparison of hematological parameters
Hypertensive groups had significantly higher median
(IQR) value of WBC, RBC, Hgb, HCT, MCV and mean
(SD) value of MCHC, RDW, MPV and PDW were sig-
nificantly higher in hypertensive patient than apparently
healthy normotensive individuals (P < 0.05). Although
the median (IQR) value of PLT count is relatively higher
in hypertensive groups, there is no statistically significant
difference between these groups (P = 0.262) (Table 2).
Correlation of hematological parameters with blood
pressure indices
In the present study correlation of the various
haematological parameters and the blood pressure in-
dices among hypertensive individuals was determined.
As Table 3 indicates WBC, RBC, Hgb, HCT and PLT
showed significant positive correlations with diastolic
blood pressure, systolic blood pressure and mean ar-
terial pressure (r = 0.282–3.96, P < 0.01).
Discussion
A total of 252 study subjects (126 Hypertensive and 126
healthy controls) were involved in this study to compare
some hematological parameters among hypertensive and
normotensive individuals. The mean age of hypertensive
and control individuals were 50.3 ± 11 and 49.8 ±
11.6 years, respectively. Based on the result, hypertensive
groups had significantly higher median (IQR) WBC
value 6.9 × 103/μl (3.7 × 103/μl) when compared to ap-
parently healthy normotensive controls 5.2 × 103/μl
(2.2 × 103/μl). This finding is in agreement with other
similar studies by Babu KR et al. [7] and Al-Muhana
et al. [19]. Also, this study showed a significant positive
correlation of WBC count with diastolic blood pressure,
systolic blood pressure and mean arterial pressure.
Table 2 Comparison of hematological parameters between hypertensive and normotensive groups at university of Gondar hospital
from October to November 2015
Variables Hypertensive (n = 126) Healthy controls (n = 126) P values
Mean ± SD Median (IQR) Mean ± SD Median (IQR)
WBC (103/μl) – 6.90 (3.70) – 5.20 (2.20) < 0.001
RBC (106/μl) – 5.00 (0.88) – 4.88 (0.58) 0.015
Hgb (g/dl) – 14.60 (1.85) – 14.15 (1.00) 0.005
HCT (%) – 42.70 (5.80) – 41.3 (3.00) < 0.001
MCV (fl) – 86.5 (6.13) – 86.00 (4.43) 0.011
PLT (103/μl) – 270.00 (101.00) – 255.50 (103.25) 0.262
MCH (pg) 29.60 ± 1.75 – 29.61 ± 1.7 – 0.937
MCHC (g/dl) 34.27 ± 1.17 – 34.7 ± 1.13 – 0.003
RDW (SD) (fl) 43.19 ± 2.62 – 42.90 ± 4.42 – < 0.001
MPV (fl) 10.0 ± 0.95 – 9.8 ± 1.0 – 0.046
PDW (fl) 12.6 ± 1.8 – 12.0 ± 1.7 – 0.007
Note: For hematological parameters expressed by median (IQR), P value is derived from Mann-Whitney U test; while those expressed by mean ± SD, P value is derived
from independent T test
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tion and different hematological disorders [17, 20]. Most
hypertensive patient’s exhibit increased blood viscosity
compared with healthy controls [14]. There is a de-
creased RBC deformability which could cause an in-
creased microvascular flow resistance, which may result
in haemolysis and organ damage [11]. This haemolysis
induces release of Hgb in to the plasma which scavenges
nitric oxide and causes endothelial dysfunction [21].
There is also functional alterations and abnormalities of
platelets in hypertension which is associated with in-
creased risk of clot formation. Activated and large plate-
lets are produced as a result of endothelial dysfunction.
These large and activated platelets produce vasoconstric-
tors. This enhances narrowing of blood vessels; there by
high blood pressure and thrombotic disease [22–25].Table 3 Correlation of haematological parameters with blood
pressure indices among hypertensives individuals at university of
Gondar hospital from October to November 2015
Variables DBP (P-value) SBP (P-value) MAP (P-value)
WBC (103/μl) 0.362 (0.000) a 0.396 (0.000) a 0.371 (0.000) a
RBC (106/μl) 0.358 (0.001) a 0.303 (0.000) a 0.301 (0.001) a
Hgb (g/dl) 0.341 (0.000) a 0.282 (0.001) a 0.286 (0.001) a
HCT (%) 0.368 (0.000) a 0.284 (0.001) a 0.300 (0.001) a
MCV (fl) −0.136 (0.130) −0.147 (0.101) −0.118 (0.189)
MCH (pg) −0.088 (0.330) −0.097 (0.282) −0.074 (0.410)
MCHC (g/dl) 0.011 (0.904) 0.030 (0.742) −0.003 (0.904)
RDW (SD) (fl) −0.031 (0.734) 0.037 (0.685) 0.085 (0.346)
PLT (103/μl) 0.376 (0.000) a 0.373 (0.000) a 0.362 (0.000) a
MPV (fl) −0.149 (0.97) −0.062 (0.489) −0.110 (0.220)
Note: aCorrelation is significant at the 0.01 level (2-tailed), P value derived
from Pearson’s and Spearman’s correlation coefficientThe relationship between WBC and hypertension may
be explained by an increased concentration of stem cell
factor (SCF) in serum [26]. During HTN, there is a vascu-
lar endothelial dysfunction [27, 28]. Thus, to repair this
dysfunction SCF/c-kit increases. The SCF has an import-
ant role in differentiation and proliferation of haematopoi-
etic cells [26, 29]. This pathway might increase WBC via
its participation in the differentiation and proliferation of
haematopoietic cells. Additionally, white blood cells are
inflammatory marker and tends to increase during HTN
which is supported by Kim D-J et al. [30]. But in contra-
diction to this study, a study conducted in São Paulo,
Brazil showed lower mean value of WBC count in hyper-
tensive individuals when compared to apparently healthy
normotensive subjects. But there was no significant asso-
ciation [31]. This difference may be due to differences in
the study subjects. The study subjects included in this
study were HTN confirmed but the study subjects in São
Paulo, Brazil were without a previous diagnosis of high
blood pressure.
Similarly, the current study showed significantly higher
median (IQR) RBC value 5 × 106/μl (0.88 × 106/μl) when
compared to apparently healthy controls 4.88 × 106/μl
(0.58 × 106/μl). This is supported by Babu KR et al. [7],
Reis RS et al. [31] and Bruschi G et al. [32]. Also, RBC
count showed significantly positive correlation with dia-
stolic blood pressure, systolic blood pressure and mean
arterial pressure. The possible mechanisms of the associ-
ation between RBC and blood pressure are not entirely
known but the study showed that it may be associated
with stem cell factor. Stem cell factor (SCF)/c-kit signal-
ing proteins are increased in hypertensive individuals
[26]. Since it is involved in repairing of damaged blood
vessels, the expression of stem cell factor (SCF)/c-kit
Enawgaw et al. BMC Hematology  (2017) 17:21 Page 5 of 7signaling proteins are relatively high during blood vessel
repair. Thus, as a result of SCF, RBC number will be in-
crease via the participation of SCF in the differentiation
and proliferation of haematopoietic cells [29].
In the present study, Hgb value was significantly in-
creased in the hypertensive group compared to normo-
tensive groups. This findings is in agreement with
supported studies done by Babu KR et al. [7] and
Al-Muhana et al. [2, 19] but it contradicts with a study
conducted in São Paulo, Brazil [31]. Hgb value has
shown a positive correlation with systolic, diastolic and
mean arterial pressure in hypertensive groups which is
similar to the study conducted by Atsma F et al. in
France [33].
The association between HTN and Hgb level may be
explained by Hgb and arginase enzyme effects on nitric
oxide (NO) bioavailability [21, 34]. During HTN, there is
a possibility of hemolysis. But, whether hemolysis is a
cause or effect of hypertension remains unclear. Most
studies suggest that hypertension is a complication of
hemolysis and associated with hemolytic anemia [35]. In
addition to this, blood disorders such as polycythemia
vera and essential thrombocythemia, causes hyperten-
sion [20]. Polycythemia vera will cause an increase in
relative red cell mass and whole blood viscosity, and
thereby increase peripheral resistance to blood flow. If
there is peripheral resistance in the microcirculation,
there will be a possibility of hemolysis [21]. During
hemolysis, hemoglobin and arginase enzyme are released
in to circulation from erythrocytes. This free Hgb is
scavenger of nitric oxide which is produced in the endo-
thelial cell that lines the blood vessels and important for
relaxation of blood vessels. On the other hand, arginase
enzyme depletes the substrate used for NO synthesis by
conversion of arginine to ornithine, thus reducing NO
production. This conditions leading to endothelial dys-
function and ultimately activation of platelets and clots
[21, 36, 37]. Therefore, if free Hgb scavenges nitric oxide
and arginase enzyme depletes substrates used for NO
production, blood vessel dilation decreases, which in
turn causes increased blood pressure.
In our study, the median (IQR) value of HCT signifi-
cantly increased in hypertensive individuals compare to
normotensive individuals. These findings are also familiar
to Babu KR et al. [7]. In bivariate correlation analysis,
HCT value has shown a positive correlation with systolic,
diastolic and MAP blood pressure in hypertensive groups.
The reasonable mechanisms underlying the association
between HCT and blood pressure is that HCT is a deter-
minant factor for high whole blood viscosity during hyper-
tension. This may lead to a peripheral resistance to blood
flow and high blood pressure [7, 11]. The evidence
showed that, most hypertensive patients exhibit increased
blood viscosity compared with healthy controls [14].Therefore, high hematocrit in hypertension could reflect a
true increase in red blood cell mass as well as hemo-
concentration caused by a reduction in plasma volume. In
contrary to aforementioned result, contradicted study
conducted at University of Port Harcourt teaching hos-
pital, Nigeria [38] and Saudi Arabia [19] reported that
HCT was not significantly differ between hypertensive pa-
tients and normotensive individuals. This difference may
be due to difference in sample size.
In our study, RDW increased significantly in hyperten-
sive groups compared to normotensive individuals. Most
studies suggest that higher RDW, which is a measure of
the variability in the circulating erythrocytes’ size, may
be resulted from ineffective erythropoiesis due to
chronic inflammation during hypertension [39, 40].
In this study MCV and MCHC were increased signifi-
cantly in hypertensive groups but there were no signifi-
cant differences in MCH. But other studies in these
parameters showed contradicted ideas. For example a
study conducted by Babu KR et al. [7] showed signifi-
cantly lower MCV, significantly higher MCHC and
higher but no difference MCH value. In São Paulo,
Brazil, MCV were similar [31], in France MCV is lower
by 2% [32] and a study in Saudi Arabia showed no sig-
nificant differences of MCV, MCH and MCHC [19].
In the present study, the median (IQR) value of PLT
count, mean value of MPV and PDW were increased in
hypertensive groups than controls. Even though statisti-
cally not significant, median value of PLT count was
slightly higher in hypertensive groups. The possible ex-
planation for this could be related to consumption of
platelets. During hypertension, there is endothelial dys-
function and this leads to platelet activation and clot for-
mation. Then platelets will be consumed and there
number does not increase as expected [25, 41, 42]. How-
ever, statistically significant increment of MPV and
PDW were found in hypertensive groups compared to
normotensive groups. This finding is in accordance with
the previous findings by Babu et al. [7], Al-Muhana et al.
[19], Bruschi et al. [32] and Ates et al. [43].
In our study, PLT count positively correlated with blood
pressure indices. The possible mechanisms might be re-
lated to vascular complication in hypertensive groups.
High blood pressure causes endothelial damage via shear
stress, which results in an increase in platelet activation
[43]. When platelet production is induced, there could be
increment in platelet count, MPV and PDW [44]. Evi-
dence suggests that PLT consumption increase at the site
of injured blood vessel. During this condition larger PLTs
would be released from the bone marrow because larger
PLTs are hemostatically more active than mature PLT. Be-
cause larger PLTs are hemostatically more active, the pres-
ence of larger PLTs is probably a risk factor for developing
coronary thrombosis and myocardial infraction [41, 42].
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and improve endothelial function, their effect didn’t as-
sess in this study. Additionally, cell free hemoglobin ana-
lysis was not considered. Therefore, further cohort study
is required.Conclusion
In the present study, the median (IQR) value of WBC,
RBC, Hgb, HCT, MCV and the mean value of MCHC,
RDW, MPV and PDW were significantly higher in the
hypertensive group compared to apparently healthy con-
trols. But platelet count and MCH showed no statisti-
cally significant difference between hypertensive and
normotensive groups. In this study there was statistically
significant positive correlations of WBC, RBC, Hgb,
HCT and PLT with blood pressure indices (diastolic
blood pressure, systolic blood pressure and mean arterial
pressure) among hypertensive individuals. Impaired
hematological parameters may strongly indicate hyper-
tensive end-organ damage. Hematological complication
such as RBCs reduction in deformability and an increase
in the size causes hemolysis, high Hgb and low levels are
associated with cardiovascular risk and activation of
platelets is risk factor for thrombotic diseases observed
during hypertension. Therefore, it is important to assess
changes in hematological parameters for hypertensive
patients which may help to prevent such complications
associated hematological disorders.Additional files
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